Suppr超能文献

酪氨酸激酶 c-Met 有助于 p38 激酶在人胆管胆管癌细胞中的促肿瘤功能。

The tyrosine kinase c-Met contributes to the pro-tumorigenic function of the p38 kinase in human bile duct cholangiocarcinoma cells.

机构信息

International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai 200438.

出版信息

J Biol Chem. 2012 Nov 16;287(47):39812-23. doi: 10.1074/jbc.M112.406520. Epub 2012 Sep 28.

Abstract

Pro-tumorigenic function of the p38 kinase plays a critical role in human cholangiocarcinogenesis. However, the underlying mechanism remains incompletely understood. Here, we report that c-Met, the tyrosine kinase receptor for hepatocyte growth factor (HGF), contributes to the pro-tumorigenic ability of p38 in human cholangiocarcinoma cells. Both p38 and c-Met promote the proliferation and invasion of human cholangiocarcinoma cells. Importantly, inhibition or knockdown of p38 decreased the basal activation of c-Met. Tyrosine phosphatase inhibitor studies revealed that p38 promotes the activity of c-Met, at least in part, by inhibiting dephosphorylation of the receptor. Moreover, density enhanced phosphatase-1 (DEP-1) is involved in p38-mediated inhibiting dephosphorylation of c-Met. Furthermore, p38 inhibits the degradation of c-Met. Taken together, these data provide a potential mechanism to explain how p38 promotes human cholangiocarcinoma cell proliferation and invasion. We propose that the link between p38 and c-Met is implicated in the progression of human cholangiocarcinoma.

摘要

p38 激酶的促肿瘤功能在人类胆管癌发生中起着关键作用。然而,其潜在的机制尚不完全清楚。在这里,我们报告 c-Met,即肝细胞生长因子(HGF)的酪氨酸激酶受体,有助于 p38 在人胆管癌细胞中的促肿瘤能力。p38 和 c-Met 均促进人胆管癌细胞的增殖和侵袭。重要的是,p38 的抑制或敲低降低了 c-Met 的基础激活。酪氨酸磷酸酶抑制剂研究表明,p38 通过抑制受体的去磷酸化至少部分地促进 c-Met 的活性。此外,密度增强磷酸酶-1(DEP-1)参与了 p38 介导的 c-Met 去磷酸化抑制。此外,p38 抑制 c-Met 的降解。总之,这些数据提供了一个潜在的机制来解释 p38 如何促进人胆管癌细胞的增殖和侵袭。我们提出,p38 和 c-Met 之间的联系与人类胆管癌的进展有关。

相似文献

1
The tyrosine kinase c-Met contributes to the pro-tumorigenic function of the p38 kinase in human bile duct cholangiocarcinoma cells.
J Biol Chem. 2012 Nov 16;287(47):39812-23. doi: 10.1074/jbc.M112.406520. Epub 2012 Sep 28.
2
3
NK4 gene therapy inhibits HGF/Met-induced growth of human cholangiocarcinoma cells.
Dig Dis Sci. 2013 Jun;58(6):1636-43. doi: 10.1007/s10620-012-2523-7. Epub 2013 Jan 12.
5
Microsomal prostaglandin E synthase-1 inhibits PTEN and promotes experimental cholangiocarcinogenesis and tumor progression.
Gastroenterology. 2011 Jun;140(7):2084-94. doi: 10.1053/j.gastro.2011.02.056. Epub 2011 Feb 24.
6
S100A11 promotes cell proliferation via P38/MAPK signaling pathway in intrahepatic cholangiocarcinoma.
Mol Carcinog. 2019 Jan;58(1):19-30. doi: 10.1002/mc.22903. Epub 2018 Oct 21.
7
Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
Gastroenterology. 2012 Apr;142(4):1021-1031.e15. doi: 10.1053/j.gastro.2011.12.005. Epub 2011 Dec 13.
8
Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes.
J Hepatol. 2006 Jun;44(6):1055-65. doi: 10.1016/j.jhep.2005.10.030. Epub 2005 Dec 13.
9
Involvement of PI3K and ERK1/2 pathways in hepatocyte growth factor-induced cholangiocarcinoma cell invasion.
World J Gastroenterol. 2010 Feb 14;16(6):713-22. doi: 10.3748/wjg.v16.i6.713.
10
The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance.
Autophagy. 2019 Jul;15(7):1258-1279. doi: 10.1080/15548627.2019.1580105. Epub 2019 Feb 20.

引用本文的文献

1
The role of mesenchymal cells in cholangiocarcinoma.
Dis Model Mech. 2024 Dec 1;17(12). doi: 10.1242/dmm.050716. Epub 2024 Dec 13.
3
Mutational spectrum and precision oncology for biliary tract carcinoma.
Theranostics. 2021 Mar 4;11(10):4585-4598. doi: 10.7150/thno.56539. eCollection 2021.
4
Mitogen-Activated Protein Kinases (MAPKs) and Cholangiocarcinoma: The Missing Link.
Cells. 2019 Sep 28;8(10):1172. doi: 10.3390/cells8101172.
5
Molecular alterations and clinical prognostic factors for cholangiocarcinoma in Thai population.
Onco Targets Ther. 2017 Oct 11;10:4955-4968. doi: 10.2147/OTT.S143982. eCollection 2017.
8
Secreted cyclophilin A mediates G1/S phase transition of cholangiocarcinoma cells via CD147/ERK1/2 pathway.
Tumour Biol. 2015 Feb;36(2):849-59. doi: 10.1007/s13277-014-2691-5. Epub 2014 Oct 10.
9
JNK contributes to the tumorigenic potential of human cholangiocarcinoma cells through the mTOR pathway regulated GRP78 induction.
PLoS One. 2014 Feb 28;9(2):e90388. doi: 10.1371/journal.pone.0090388. eCollection 2014.
10

本文引用的文献

3
Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma.
Br J Cancer. 2011 Jun 28;105(1):131-8. doi: 10.1038/bjc.2011.199. Epub 2011 Jun 14.
4
c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma.
Hepatology. 2011 Sep 2;54(3):879-89. doi: 10.1002/hep.24450. Epub 2011 Jul 19.
5
Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3 signaling.
J Biol Chem. 2011 Apr 1;286(13):10918-29. doi: 10.1074/jbc.M110.205021. Epub 2011 Jan 24.
6
MET signalling: principles and functions in development, organ regeneration and cancer.
Nat Rev Mol Cell Biol. 2010 Dec;11(12):834-48. doi: 10.1038/nrm3012.
9
Signal integration by JNK and p38 MAPK pathways in cancer development.
Nat Rev Cancer. 2009 Aug;9(8):537-49. doi: 10.1038/nrc2694.
10
Analysis of receptor tyrosine kinase internalization using flow cytometry.
Methods Mol Biol. 2008;457:305-17. doi: 10.1007/978-1-59745-261-8_23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验